$JRSS
JRSIS HEALTH CARE Corp

2023 Q2 Form 10-K Financial Statement

#000121390023030047 Filed on April 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q4 2022
Revenue $43.32K $89.17K $89.17K
YoY Change -99.32% -99.8%
Cost Of Revenue $297.8K $1.693M
YoY Change -81.39%
Gross Profit $39.61K $26.21K
YoY Change -99.93%
Gross Profit Margin 91.44% 29.4%
Selling, General & Admin $140.0K $127.5K $371.7K
YoY Change 39.5% -96.35% -97.18%
% of Gross Profit 353.44% 1418.03%
Research & Development $38.34K $283.0K
YoY Change
% of Gross Profit 96.8% 1079.86%
Depreciation & Amortization $0.00 $2.130K $5.796K
YoY Change -100.0% -99.75% -99.83%
% of Gross Profit 0.0% 22.11%
Operating Expenses $150.0K $133.0K $415.1K
YoY Change 17.84% -98.52% -98.61%
Operating Profit -$105.0K -$325.9K
YoY Change -17.51% -105.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$1.740K $981.9K
YoY Change -100.57% 267.79%
Pretax Income -$105.0K -$45.56K -$327.6K
YoY Change -17.51% -102.97% -107.5%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$105.0K -$45.56K $2.334M
YoY Change -17.51% -105.24% 4.54%
Net Earnings / Revenue -242.41% -51.09% 2617.03%
Basic Earnings Per Share -$0.02 -$0.75
Diluted Earnings Per Share -$0.02 $0.00 -$0.75
COMMON SHARES
Basic Shares Outstanding 58.37M shares 58.37M shares 44.89M shares
Diluted Shares Outstanding 5.837M shares 44.89M shares

Balance Sheet

Concept 2023 Q2 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.00K $58.62K $58.62K
YoY Change -20.34% -93.15% -93.15%
Cash & Equivalents $28.22K $58.62K $58.62K
Short-Term Investments
Other Short-Term Assets $570.0K $736.4K $736.4K
YoY Change -36.67% -77.5% -77.5%
Inventory $562.0K
Prepaid Expenses
Receivables $13.79K
Other Receivables $2.841K $2.987K
Total Short-Term Assets $617.6K $798.9K $798.9K
YoY Change -35.3% -94.24% -94.24%
LONG-TERM ASSETS
Property, Plant & Equipment $33.05K $38.99K $57.13K
YoY Change -25.76% -99.93% -99.9%
Goodwill
YoY Change
Intangibles $303.2K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $43.78K $57.13K $57.13K
YoY Change -38.76% -99.91% -99.91%
TOTAL ASSETS
Total Short-Term Assets $617.6K $798.9K $798.9K
Total Long-Term Assets $43.78K $57.13K $57.13K
Total Assets $661.4K $856.0K $856.0K
YoY Change -35.54% -98.87% -98.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.000K $24.71K $24.71K
YoY Change 0.0% -99.8% -99.8%
Accrued Expenses $10.00K $18.52K $18.52K
YoY Change -45.56% -99.01% -99.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $49.71K
YoY Change -97.33%
Total Short-Term Liabilities $69.39K $43.23K $43.23K
YoY Change 163.12% -99.75% -99.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00 $1.430K $1.430K
YoY Change -100.0% -99.97% -99.97%
Total Long-Term Liabilities $0.00 $1.430K $1.430K
YoY Change -100.0% -99.99% -99.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $69.39K $43.23K $43.23K
Total Long-Term Liabilities $0.00 $1.430K $1.430K
Total Liabilities $69.39K $44.66K $44.66K
YoY Change 89.84% -99.92% -99.92%
SHAREHOLDERS EQUITY
Retained Earnings -$23.93M -$23.71M
YoY Change 1.71% 1162.76%
Common Stock $583.00 $58.37K
YoY Change -99.0% 213.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $592.0K $811.3K $811.3K
YoY Change
Total Liabilities & Shareholders Equity $661.4K $856.0K $856.0K
YoY Change -35.54% -98.87% -98.87%

Cashflow Statement

Concept 2023 Q2 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$105.0K -$45.56K $2.334M
YoY Change -17.51% -105.24% 4.54%
Depreciation, Depletion And Amortization $0.00 $2.130K $5.796K
YoY Change -100.0% -99.75% -99.83%
Cash From Operating Activities $10.00K $67.33K $3.067M
YoY Change -100.4% -92.12% -62.75%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$1.730K $44.64K
YoY Change -100.0% -100.15% -101.94%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$2.783M
YoY Change -100.0% -100.0% -12.89%
Cash From Investing Activities $0.00 $1.720K -$2.828M
YoY Change -100.0% -99.82% -48.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 -$738.2K
YoY Change -100.0% -100.0% -73.62%
NET CHANGE
Cash From Operating Activities 10.00K 67.33K $3.067M
Cash From Investing Activities 0.000 1.720K -$2.828M
Cash From Financing Activities 0.000 0.000 -$738.2K
Net Change In Cash 10.00K 69.05K -$797.4K
YoY Change -100.67% -73.5% 1118.45%
FREE CASH FLOW
Cash From Operating Activities $10.00K $67.33K $3.067M
Capital Expenditures $0.00 -$1.730K $44.64K
Free Cash Flow $10.00K $69.06K $3.022M
YoY Change -100.28% -121.92% -71.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
usd
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
usd
CY2021Q4 jrss Capital Lease Obligations Current Portion
CapitalLeaseObligationsCurrentPortion
usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
usd
CY2021 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
usd
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-56013
CY2022 dei Entity Registrant Name
EntityRegistrantName
JRSIS HEALTH CARE CORPORATION
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4562047
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
3/F Building A
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
De Run YuanNo. 19 Chang Yi Road
CY2022 dei Entity Address Address Line3
EntityAddressAddressLine3
Chang Ming ShuiWu Gui Shan
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Zhong Shan City
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
528458
CY2022 dei City Area Code
CityAreaCode
+86
CY2022 dei Local Phone Number
LocalPhoneNumber
760-88963658
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
786560 usd
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58366569 shares
CY2022 dei Auditor Firm
AuditorFirmId
2769
CY2022 dei Auditor Name
AuditorName
Centurion ZD CPA & Co.
CY2022 dei Auditor Location
AuditorLocation
Hong Kong
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58616 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29847 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2987 usd
CY2022Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
854 usd
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
736393 usd
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
13836084 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
798850 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
13865931 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38989 usd
CY2022Q4 jrss Right Of Use Asset Net Noncurrent
RightOfUseAssetNetNoncurrent
18138 usd
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
61826821 usd
CY2022Q4 us-gaap Assets
Assets
855977 usd
CY2021Q4 us-gaap Assets
Assets
75692752 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
24711 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
66000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1456919 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1812 usd
CY2022Q4 jrss Capital Lease Obligations Current Portion
CapitalLeaseObligationsCurrentPortion
16708 usd
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
16076570 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43231 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17599502 usd
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
7 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1430 usd
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
24991063 usd
CY2022Q4 us-gaap Liabilities
Liabilities
44661 usd
CY2021Q4 us-gaap Liabilities
Liabilities
42590572 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58366569 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58366569 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18628569 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18628569 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
58366 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
18628 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24452501 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23381121 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23705746 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1877296 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6195 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
545449 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
811316 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22067902 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
11034278 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
811316 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
33102180 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
855977 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75692752 usd
CY2022 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
89166 usd
CY2022 us-gaap Revenues
Revenues
89166 usd
CY2022 jrss Rentals And Leases
RentalsAndLeases
14712 usd
CY2022 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
245465 usd
CY2022 us-gaap Supplies Expense
SuppliesExpense
37582 usd
CY2021 us-gaap Supplies Expense
SuppliesExpense
7242 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
13312 usd
CY2022 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1400 usd
CY2022 us-gaap Professional Fees
ProfessionalFees
96795 usd
CY2021 us-gaap Professional Fees
ProfessionalFees
97701 usd
CY2022 jrss Warrant Expense
WarrantExpense
-7 usd
CY2021 jrss Warrant Expense
WarrantExpense
-1142 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5796 usd
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
415055 usd
CY2021 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
103801 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-325889 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-103801 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1741 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-327630 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103801 usd
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-327630 usd
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-103801 usd
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33393670 usd
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
3292746 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-33721300 usd
CY2021 us-gaap Profit Loss
ProfitLoss
3188945 usd
CY2022 jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-17396 usd
CY2021 jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-55624 usd
CY2022 jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-301922 usd
CY2021 jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-875758 usd
CY2022 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33401982 usd
CY2021 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
4120327 usd
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0073
CY2021 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0056
CY2022 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0073
CY2021 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0056
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.744
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.1785
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.744
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.1764
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7513
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.1728
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7513
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.1709
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44885402 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18451588 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44885402 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18661588 shares
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28840425 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
3188945 usd
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
141428 usd
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
931382 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
33102180 usd
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-34984724 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2333505 usd
CY2022 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1056510 usd
CY2022 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
60000 usd
CY2022 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-970560 usd
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
214405 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
811316 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-33721300 usd
CY2021 us-gaap Profit Loss
ProfitLoss
3188945 usd
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33393670 usd
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
3292746 usd
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-327630 usd
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-103801 usd
CY2022 us-gaap Depreciation
Depreciation
5796 usd
CY2022 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
13312 usd
CY2022 us-gaap Other Noncash Expense
OtherNoncashExpense
1400 usd
CY2022 jrss Warrant Expenses
WarrantExpenses
-7 usd
CY2021 jrss Warrant Expenses
WarrantExpenses
-1142 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
245465 usd
CY2022 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
854 usd
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
2987 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-41289 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2000 usd
CY2021 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-2298 usd
CY2022 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1812 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-104982 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-109241 usd
CY2022 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
3171627 usd
CY2021 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
8342256 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3066645 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8233016 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44644 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-44644 usd
CY2022 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-2783041 usd
CY2021 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-5500437 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2827685 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5500437 usd
CY2022 jrss Noncash Issuance Of Common Stocks
NoncashIssuanceOfCommonStocks
69260 usd
CY2021 jrss Noncash Issuance Of Common Stocks
NoncashIssuanceOfCommonStocks
141428 usd
CY2022 jrss Derivative Financial Instrument
DerivativeFinancialInstrument
-60000 usd
CY2022 jrss Derivative Financial Instruments
DerivativeFinancialInstruments
7 usd
CY2021 jrss Derivative Financial Instruments
DerivativeFinancialInstruments
1142 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129267 usd
CY2022 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-867508 usd
CY2021 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-2940594 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-738241 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2798024 usd
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-298074 usd
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76589 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-797355 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11144 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
855971 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
844827 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58616 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
855971 usd
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
58616 usd
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
29847 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
826124 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58616 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
855971 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
13086 usd
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-25275 usd
CY2022 us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
406544 usd
CY2021 us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
1381761 usd
CY2022 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1056510 usd
CY2022 us-gaap Stock Issued1
StockIssued1
970560 usd
CY2022Q2 jrss Equity Method Investment Ownership Percent
EquityMethodInvestmentOwnershipPercent
0.70 pure
CY2022Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
5392000 shares
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
14712 usd
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1155662 usd
CY2021 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
1155662 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>C. Use of estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>E. Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The majority of sales are either cash receipt in advance or cash receipt upon delivery. As of December 31, 2022 and 2021, no customer accounted for more than 5% of net accounts receivable. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited. For the year ended December 31, 2022, one customer accounted for 100% of total revenue. For the year ended December 31, 2021, no customers accounted for more than 5% of total revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022 jrss Summary Of Changes In Warrant Liability Table Textblock
SummaryOfChangesInWarrantLiabilityTableTextblock
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; text-align: justify"><span style="font-size: 10pt">Balance at January 1, 2022</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 8%; text-align: right"><span style="font-size: 10pt">7</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Change in fair value of warrant liability</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(7</span></td> <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">Balance at December 31, 2022</span></td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-size: 10pt">-</span></td> <td style="padding-bottom: 4pt"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <b> </b></p>
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7 usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7 usd
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
usd
CY2022Q2 jrss Negotiated Value
NegotiatedValue
1056510 usd
CY2022Q2 us-gaap Other Additional Capital
OtherAdditionalCapital
74652 usd
CY2022Q2 us-gaap Other Expenses
OtherExpenses
981858 usd
CY2022Q2 jrss Expense Term Year
ExpenseTermYear
P3Y
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
245465 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.25 pure
CY2022 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>O. Reclassification</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The comparative figures before April 1, 2022 have been reclassified to conform to current year presentation to reflect the disposal of a component of business derived from the recognition of a spin-off transaction on April 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022 us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.70 pure
CY2022Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
5392000 shares
CY2021 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
usd
CY2021 us-gaap Revenues
Revenues
usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
44644 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5655 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
38989 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5796 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1528 usd
CY2022Q4 jrss Net Lease Assets
NetLeaseAssets
18138 usd
CY2022Q4 jrss Net Lease Liabilities
NetLeaseLiabilities
18138 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
18138 usd
CY2022Q4 jrss Total Lease Assets
TotalLeaseAssets
18138 usd
CY2022Q4 jrss Lease Liabilities Current
LeaseLiabilitiesCurrent
16708 usd
CY2022Q4 jrss Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
1430 usd
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
18138 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16708 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1430 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18138 usd
CY2022 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
89166 usd
CY2022 us-gaap Revenues
Revenues
89166 usd
CY2022Q4 us-gaap Due From Other Related Parties
DueFromOtherRelatedParties
854 usd
CY2021 jrss Rentals And Leases
RentalsAndLeases
usd
CY2021 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
usd
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1456919 usd
CY2022 jrss Negotiated Value
NegotiatedValue
1056510 usd
CY2022Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
74652 usd
CY2022 us-gaap Other Expenses
OtherExpenses
981858 usd
CY2022 jrss Expense Term Year
ExpenseTermYear
P3Y
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
245465 usd
CY2022Q1 jrss Owned Percentage
OwnedPercentage
1 pure
CY2022Q2 us-gaap Shares Issued
SharesIssued
39130000 shares
CY2022Q2 jrss Acquired Shares
AcquiredShares
8000000 shares
CY2022Q2 jrss Owned Shares
OwnedShares
47130000 shares
CY2022Q2 jrss Common Stock Percentage
CommonStockPercentage
0.807 pure
CY2022Q1 jrss Total Share Issued
TotalShareIssued
6000000 shares
CY2022Q1 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
60000 usd
CY2022Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.01
CY2022Q2 jrss Transfer Agreement Description
TransferAgreementDescription
Runteng entered into an agreement regarding a transfer of Harbin Jiarun Hospital Co., Ltd.’s Equity (the “Transfer Agreement”) with Zhang Junsheng. Pursuant to the Transfer Agreement, Runteng transferred to Mr. Zhang equity in Harbin Jiarun Hospital Co., Ltd. (“Jiarun Hospital”) representing 70% of the total equity in Jiarun Hospital and Mr. Zhang transferred to Runteng 5,392,000 shares of the Company’s common stock. On May 27, 2022, the Company cancelled 5,392,000 shares of its common stock from Zhang Junsheng. Since this transaction required certain authoritative approval before effective, the publication of these transactions was delayed so as to obtain all parties’ consent and advance authoritative approval. As of May 27, 2022, the issued share balance of the Company was 58,366,569, the balance of the number of shares of Mr. Zhang and Mr. Zhong were nil (0%) and 47,130,000 (80.7%), respectively.
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58366569 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58366569 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18628569 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18628569 shares
CY2022 jrss Substantial Loss
SubstantialLoss
33701300 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23705746 usd
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
usd
CY2021Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
usd
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2021Q4 jrss Right Of Use Asset Net Noncurrent
RightOfUseAssetNetNoncurrent
usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
usd
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
usd
CY2021 us-gaap Depreciation
Depreciation
usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
usd
CY2021 jrss Derivative Financial Instrument
DerivativeFinancialInstrument
usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022 us-gaap Interest Expense
InterestExpense
usd
CY2021 us-gaap Interest Expense
InterestExpense
usd
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
CY2021 us-gaap Stock Issued1
StockIssued1
usd
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
usd
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
usd
CY2022 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
usd
CY2021 us-gaap Revenues
Revenues
usd
CY2021Q4 us-gaap Due From Other Related Parties
DueFromOtherRelatedParties
usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
usd
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001597892

Files In Submission

Name View Source Status
0001213900-23-030047-index-headers.html Edgar Link pending
0001213900-23-030047-index.html Edgar Link pending
0001213900-23-030047.txt Edgar Link pending
0001213900-23-030047-xbrl.zip Edgar Link pending
f10k2022ex21_jrsishealth.htm Edgar Link pending
f10k2022ex31-1_jrsishealth.htm Edgar Link pending
f10k2022ex31-2_jrsishealth.htm Edgar Link pending
f10k2022ex32-1_jrsishealth.htm Edgar Link pending
f10k2022ex32-2_jrsishealth.htm Edgar Link pending
f10k2022_jrsishealth.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
jrss-20221231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
jrss-20221231_cal.xml Edgar Link unprocessable
jrss-20221231_lab.xml Edgar Link unprocessable
jrss-20221231_def.xml Edgar Link unprocessable
jrss-20221231_pre.xml Edgar Link unprocessable
f10k2022_jrsishealth_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending